July 12, 2018 / 11:13 AM / 2 months ago

Zogenix's treatment for rare epilepsy meets advanced study goal

July 12 (Reuters) - Zogenix Inc said on Thursday its drug to treat Dravet syndrome, a rare form of epilepsy, met the main goal of a late-stage trial.

The study, the second late-stage trial of the drug, found that the treatment led to a reduction in reduction in mean monthly seizures, when compared with a placebo. (Reporting by Manas Mishra Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below